Neurodegenerative
CuraAX aims to address debilitating blood pressure drops and cognitive symptoms of nOH Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056) in a Phase 2a proof-of-concept trial…
Read More
Results reinforce telitacicept’s potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that its collaborator, RemeGen Co., Ltd (HKEX: 9995,…
Read More
Excerpt from the Press Release: NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced results showing that implementing a blood-based pTau217 screening assay reduced Acumen’s overall clinical trial…
Read More
January 30, 2025 Alterity Therapeutics – Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions – – ATH434 Demonstrated a Favorable Safety Profile – Excerpt…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new interim data from the ongoing open-label,…
Read More
Excerpt from the Press Release: MELBOURNE, Australia and SAN FRANCISCO, March 16, 2023 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant has been dosed in the U.S. in the Company’s Phase 2 clinical trial…
Read More
Over 49 weeks of DNL310 (ETV:IDS) treatment in the Phase 1/2 study, positive changes across measures of exploratory clinical outcomes including VABS-II (adaptive behavior) and BSID-III (cognitive capabilities) scores and global impression scales were observed Interim Phase 1/2 data also suggest that DNL310 improves hearing, as assessed by auditory brainstem response testing Additional biomarker data…
Read More
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus reads of digitized biopsy images by the central pathologists replicated the positive primary endpoint resultsThese data will be presented at the NASH-TAG Conference on Friday January 6th, 2023 Excerpt from…
Read More
Unique Combination of Beta2 Adrenoceptor Agonist (CST-103) and Beta Blocker (CST-107) Eliminated Known Agonist Adverse Events, Establishing Foundation for Longer-Term Clinical Studies Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced today positive top-line safety, tolerability and proof of concept data,…
Read More
AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease Study results in healthy volunteers demonstrated that AL101 increased the level of PGRN, a key regulator of immune activity and lysosomal function in the brain Excerpt from the Press Release: SOUTH SAN FRANCISCO,…
Read More